[Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder].
We report a 44-year-old female patient with attention deficit hyperactivity disorder (ADHD), combined subtype (DSM-IV: 314.01), who was treated with 0.5 mg of short-acting immediate-release methylphenidate/kg body weight given t.i.d. (total daily MPH IR dosage 45 mg). Under this medication, the patient reported significant reduction of symptoms. However, several times a day she experienced severe rebound phenomena with pronounced concentration disturbances, unrest, and dysphoric mood. After changing the medication to long-acting methylphenidate once daily (total daily OROS MPH dosage 54 mg), the rebound phenomena stopped, with equivalent beneficial clinical effects.
Sobanski
E
E
Klinik für Psychiatrie und Psychotherapie, Zentralinstitut für Seelische Gesundheit, Mannheim. sobanski@kv.zi-mannheim.de
Alm
B
B
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000145:classification; D005260:Female; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage* / Q000145:classification; D016896:Treatment Outcome
D000697:Central Nervous System Stimulants; D008774:Methylphenidate